(NASDAQ: MXCT) Maxcyte's forecast annual revenue growth rate of 12.52% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.67%.
Maxcyte's revenue in 2026 is $31,051,000.On average, 8 Wall Street analysts forecast MXCT's revenue for 2026 to be $3,390,427,073, with the lowest MXCT revenue forecast at $3,125,290,330, and the highest MXCT revenue forecast at $3,721,202,964. On average, 8 Wall Street analysts forecast MXCT's revenue for 2027 to be $3,914,817,806, with the lowest MXCT revenue forecast at $3,529,858,658, and the highest MXCT revenue forecast at $4,207,613,812.
In 2028, MXCT is forecast to generate $4,616,516,801 in revenue, with the lowest revenue forecast at $3,927,099,345 and the highest revenue forecast at $5,296,955,317.